PAX8 and gastric neoplasm: In brief, 47.22% (17/36) of stomach cancer patients was accompanied with SOX13 and PAX8 overexpression, while only 22.22% (8/36) of patients showed a lower expression of PAX8 and SOX13 (Fig. 2b), indicating the probability that PAX8 shared the same expression pattern as SOX13 in stomach cancer.